"Covid-19 has made 2020 into a year like no other with 'stay at home' orders and working from home the new normal. Nonetheless, the tech and pharma industries continued to attract immense antitrust scrutiny, with daily reports in the media and pressure from politicians to address what some perceive to be anticompetitive mergers by digital platforms and pharmaceutical companies, even while innovation in both sectors continues at breakneck speed. In this article, we discuss some of the most noteworthy trends and developments in the high-tech and pharma sectors over the past year, with an eye towards the unique issues that are driving antitrust enforcement in the technology area."

Read the chapter

An extract from GCR's Americas Antitrust Review 2021, first published in October 2020. The whole publication is available on Global Competition Review's website

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.